- Home
- SOPH vs AMRN Comparison
SOPH vs AMRN Comparison
Compare SOPH & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | AMRN |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | Switzerland | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 287.9M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SOPH | AMRN |
|---|---|---|
| Price | $8.17 | $13.64 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $7.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 624.4K | 76.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.21 | $12.96 |
| 52 Week High | $8.98 | $20.90 |
Technical Indicators
Market Signals| Indicator | SOPH | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 42.10 |
| Support Level | $4.63 | $13.48 |
| Resistance Level | $8.98 | $14.50 |
| Average True Range (ATR) | 0.43 | 0.40 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 58.12 | 37.76 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.